MeSH tree: C12.050.351.937.820.535.160
HSE researchers have found genes characteristic of the most aggressive subtype of clear cell renal carcinoma. Having studied data on tumor samples from 456 patients, Grigory Puzanov, research fellow at the HSE Faculty of ...
Nov 16, 2022
0
94
A normal process called cell competition, in which healthy tissues eliminate unhealthy cells, could be responsible for cancer relapses in patients months or years after they were declared cancer-free, a new study by UT Southwestern ...
Nov 8, 2022
0
55
Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient's chances of survival. This is shown by researchers from ...
Oct 17, 2022
0
66
Expected to be diagnosed in 2% of men and 1% of women in the U.S., kidney cancer has traditionally been one of the most challenging cancers to treat. Until 2005, only one drug had been approved by the Food and Drug Administration ...
Oct 14, 2022
0
59
DNA damage is one of the foundational causes of cancer. But researchers have now found that deliberately causing DNA damage—by delivering additional treatments like radiotherapy—could improve the effectiveness of immunotherapy ...
Sep 20, 2022
0
71
Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse, according ...
Sep 14, 2022
0
43
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of neoadjuvant immunotherapy in patients with kidney cancer. Patients with high-risk renal ...
Sep 8, 2022
0
57
Kidney cancer is not always confined to the kidney. In advanced cases, this cancer invades the body's biggest vein, the inferior vena cava (IVC), which carries blood out of the kidneys back to the heart. Via the IVC, cancer ...
Aug 19, 2022
0
71
Kinase activity is frequently altered in renal cell carcinoma (RCC), and tyrosine kinase inhibitors (TKIs) are part of the standard treatment strategy in patients with metastatic disease. However, there are still no established ...
Aug 17, 2022
0
48
An international group of researchers investigated why mutations often associated with renal cancer result specifically in renal cancer, instead of other cancer types.
Aug 9, 2022
0
112
